Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Regeneron Pharmaceuticals : ($REGN) Dips as Biotech Stocks Rebound

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/27/2017 | 02:09pm CEST
Thanks to renewed interest in biotech stocks, the index rose sharply last week. Gilead Sciences (NASDAQ: GILD), an underdog for over a year and Valeant Pharmaceuticals (NYSE: VRX) are notable gainers in the last week. The rally may lose steam, though, and will depend on what the U.S. government does with restructuring and reforming the health-care program.

Biotech stocks depend on the government cutting red tape and easing regulations for drug approvals. If the government does not enforce a tough pricing law for drugs, that would help the industry. Within the sector, Regeneron Pharmaceuticals (NASDAQ: REGN) is worth looking at more closely. On June 21, its competitor, Novartis (NYSE: NVS), released positive data for its RTH258 clinical study. Regeneron’s Dupixent, which treats atopic dermatitis, is a likely big revenue generator for the company. The disadvantage of the drug is the need for its administration through injection. Novartis’ product could have an edge here.

Regeneron has other key products. Praluent, which treats diabetics, holds promise. The clinical study, in Phase 3b/4 demonstrated cholesterol levels declining when 75 mg is taken every two weeks.

Takeaway
Investors should not treat every biotech stock rebound equally. Regeneron has multiple blockbuster products that will accelerate the stock price as revenue grows in the years ahead.

Copyright © 2017 Baystreet.ca Media Corp. All rights reserved., source Standard Equities Feed

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
02:09p REGENERON PHARMACEUTICALS : ($REGN) Dips as Biotech Stocks Rebound
06/23 Sonic, Forestar post gains; BlackBerry, Regeneron fall
06/23 MARKETS RIGHT NOW : US stocks open slightly lower
06/23 REGENERON PHARMACEUTICALS : Details Royalty Agreement with Novartis for Canakinu..
06/22 REGENERON PHARMACEUTICALS : Patent Issued for Method for Detecting the Replaceme..
06/22 REGENERON PHARMACEUTICALS : Patent Issued for Stabilized Formulations Containing..
06/22 REGENERON PHARMACEUTICALS : Recent Findings from Regeneron Pharmaceuticals Inc. ..
06/22 NASDAQ 100 MOVERS : Ca, regn
06/22 REGENERON PHARMACEUTICALS : Details Royalty Agreement with Novartis for Canakinu..
06/21 MARKETS RIGHT NOW : Stocks open slightly higher
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
06/14 JOHNSON & JOHNSON : flu drug succeeds in mid-stage trial
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07:11a Regeneron and Sanofi's Kevzara OK'd in Europe for rheumatoid arthritis
06/26 BIOTECH BOOM! : Overview And Company-By-Company Review
06/26 Premarket analyst action - healthcare
06/23 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 23, 2017
06/22 Cantos Could Make Ilaris A Blockbuster
Advertisement
Financials ($)
Sales 2017 5 478 M
EBIT 2017 2 173 M
Net income 2017 1 018 M
Finance 2017 2 110 M
Yield 2017 -
P/E ratio 2017 58,54
P/E ratio 2018 46,12
EV / Sales 2017 9,62x
EV / Sales 2018 8,45x
Capitalization 54 836 M
More Financials
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 464 $
Spread / Average Target -10,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..40.93%54 987
AMGEN18.78%126 856
CELGENE CORPORATION15.64%104 873
GILEAD SCIENCES-0.52%92 150
VERTEX PHARMACEUTICALS81.09%33 251
ACTELION23.36%30 469
More Results